The use of agonistic anti-CD40 therapy in treatments for cancer
Abstract
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in orderto elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of actionof agonistic anti-CD40, the use of mouse models to investigate its effects and combinations withother therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody withchemotherapy and/or other immunotherapies.
Citation
Source Title
Additional URLs
ISSN
School
Collection
Related items
Showing items related by title, author, creator and subject.
-
Khong, A.; Nelson, Delia; nowak, A.; Lake, R.; Robinson, B. (2012)Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to its action on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowing them to prime effective ...
-
Jackaman, Connie; Nelson, Delia (2012)Targeting interleukin-2 (IL-2) and/or agonist anti-CD40 antibody (Ab) into tumors represents an effective vaccination strategy that avoids systemic toxicity and resolves treated-site tumors. Here, we examined IL-2 and/or ...
-
Jackaman, Connie; Nelson, Delia (2012)Targeting interleukin-2 (IL-2) and/or agonist anti-CD40 antibody (Ab) into tumors represents an effective vaccination strategy that avoids systemic toxicity and resolves treated-site tumors. Here, we examined IL-2 and/or ...